• Lantern Pharma highlighted its RADR AI platform, targeting a 70% cut in early-stage development timelines and an 80% reduction in costs.
• RADR was cited as predicting and stratifying real-world trial patients with 88% accuracy, supporting biomarker-driven enrollment strategies.
• Lead program LP-300 is in a Phase 2 trial in never-smoker NSCLC, with preliminary data showing an 86% clinical benefit rate.
• LP-300 showed a median progression-free survival of 8.4 months in an EGFR exon 21 L858R cohort; disease control rate was 87%.
• Pipeline update included LP-284 in Phase 1 for recurrent lymphomas and soft tissue sarcomas; LP-184 advanced solid-tumor trials planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.